A Multi-Center, Open-Label, Single-Arm Study to Investigate the Early Effectiveness of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Using a Mobile Self-Monitoring Application.
Pharmaceuticals August 30, 2024 Junhyung Kim, Seung-Hoon Lee, Cheolmin Shin et al. 8 citations
This study assesses the early effectiveness of esketamine nasal spray (ESK) in adults with treatment-resistant depression (TRD) 1 day after the first administration, as monitored through self-assessment via the mobile application, Esketamine Continuing Assessment for Relapse Prevention (EsCARe). In this multi-center, open-label, single-arm study, adults aged 18-65 years diagnosed with TRD after...
DOI: 10.3390/ph17091143 (opens in new tab)
Full text (opens in new tab)
Treatment-resistant depression
Early effectiveness
Mobile health
Self-monitoring
+6